Episode: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Description: Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.
Click any word to see translations, usage examples & similar words. Then learn them using saved words.
Text not synced with the audio? See here for why certain podcasts won't sync.
